Trade Oyster Point Pharma, Inc. - OYST CFD
Market information is presented
as of 2023-09-21
- Summary
Spread | 0.07 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026151% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003929% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
*Information provided by Capital.com
Oyster Point Pharma Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Prev. Close* | 11.12 |
Open* | 11.13 |
1-Year Change* | -39.18% |
Day's Range* | 11.12 - 11.14 |
52 wk Range | 3.46-19.98 |
Average Volume (10 days) | 429.94K |
Average Volume (3 months) | 6.72M |
Market Cap | 299.85M |
P/E Ratio | -100.00K |
Shares Outstanding | 26.84M |
Revenue | 19.58M |
EPS | -6.64 |
Dividend (Yield %) | N/A |
Beta | -100.00K |
Next Earnings Date | Feb 22, 2023 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Dec 30, 2022 | 11.14 | 0.00 | 0.00% | 11.14 | 11.16 | 11.09 |
Dec 29, 2022 | 11.12 | -0.02 | -0.18% | 11.14 | 11.15 | 11.12 |
Dec 28, 2022 | 11.13 | 0.02 | 0.18% | 11.11 | 11.15 | 11.11 |
Dec 27, 2022 | 11.14 | 0.04 | 0.36% | 11.10 | 11.15 | 11.09 |
Dec 23, 2022 | 11.09 | 0.04 | 0.36% | 11.05 | 11.15 | 10.99 |
Dec 22, 2022 | 11.14 | 0.10 | 0.91% | 11.04 | 11.14 | 11.03 |
Dec 21, 2022 | 11.05 | -0.01 | -0.09% | 11.06 | 11.10 | 11.03 |
Dec 20, 2022 | 11.04 | -0.03 | -0.27% | 11.07 | 11.09 | 11.04 |
Dec 19, 2022 | 11.04 | -0.06 | -0.54% | 11.10 | 11.10 | 11.04 |
Dec 16, 2022 | 11.09 | -0.01 | -0.09% | 11.10 | 11.16 | 11.07 |
Dec 15, 2022 | 11.12 | 0.01 | 0.09% | 11.11 | 11.14 | 11.09 |
Dec 14, 2022 | 11.14 | 0.05 | 0.45% | 11.09 | 11.15 | 11.08 |
Dec 13, 2022 | 11.09 | 0.00 | 0.00% | 11.09 | 11.10 | 11.06 |
Dec 12, 2022 | 11.07 | -0.02 | -0.18% | 11.09 | 11.10 | 11.02 |
Dec 9, 2022 | 11.09 | 0.00 | 0.00% | 11.09 | 11.11 | 11.08 |
Dec 8, 2022 | 11.08 | -0.01 | -0.09% | 11.09 | 11.10 | 11.08 |
Dec 7, 2022 | 11.09 | 0.00 | 0.00% | 11.09 | 11.16 | 11.08 |
Dec 6, 2022 | 11.10 | 0.01 | 0.09% | 11.09 | 11.11 | 11.08 |
Dec 5, 2022 | 11.08 | -0.05 | -0.45% | 11.13 | 11.14 | 11.08 |
Dec 2, 2022 | 11.09 | 0.00 | 0.00% | 11.09 | 11.17 | 11.09 |
Oyster Point Pharma, Inc. Events
Time (UTC) | Country | Event |
---|---|---|
Wednesday, November 8, 2023 | ||
Time (UTC) 21:00 | Country US
| Event Q3 2023 Oyster Point Pharma Inc Earnings Release Q3 2023 Oyster Point Pharma Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total revenue | 24.539 | 0 | 0 | 0 | 0 |
Total Operating Expense | 121.194 | 70.989 | 47.301 | 16.736 | 6.86 |
Selling/General/Admin. Expenses, Total | 95.435 | 31.178 | 13.673 | 2.981 | 2.051 |
Research & Development | 24.234 | 39.811 | 33.628 | 13.755 | 3.632 |
Unusual Expense (Income) | 0 | 1.177 | |||
Operating Income | -96.655 | -70.989 | -47.301 | -16.736 | -6.86 |
Interest Income (Expense), Net Non-Operating | -3.734 | 0 | 1.59 | 0.233 | 0.259 |
Net Income Before Taxes | -100.659 | -70.52 | -45.711 | -16.503 | -6.601 |
Net Income After Taxes | -100.659 | -70.52 | -45.711 | -16.503 | -6.601 |
Net Income Before Extra. Items | -100.659 | -70.52 | -45.711 | -16.503 | -6.601 |
Net Income | -100.659 | -70.52 | -45.711 | -16.503 | -6.601 |
Total Adjustments to Net Income | 0 | -12.543 | |||
Income Available to Common Excl. Extra. Items | -100.659 | -70.52 | -45.711 | -16.503 | -19.144 |
Income Available to Common Incl. Extra. Items | -100.659 | -70.52 | -45.711 | -16.503 | -19.144 |
Diluted Net Income | -100.659 | -70.52 | -45.711 | -16.503 | -19.144 |
Diluted Weighted Average Shares | 26.0365 | 24.1286 | 21.3669 | 20.6123 | 20.6123 |
Diluted EPS Excluding Extraordinary Items | -3.86607 | -2.92267 | -2.13933 | -0.80064 | -0.92877 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | |||
Diluted Normalized EPS | -3.86607 | -2.92267 | -2.13933 | -0.80064 | -0.87166 |
Other, Net | -0.27 | 0.469 | |||
Revenue | 24.539 | ||||
Cost of Revenue, Total | 1.525 | ||||
Gross Profit | 23.014 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total revenue | 2.704 | 6.596 | 17.943 | 0 | 0 |
Total Operating Expense | 44.915 | 45.537 | 34.711 | 22.026 | 18.92 |
Selling/General/Admin. Expenses, Total | 39.898 | 38.55 | 28.497 | 15.296 | 13.092 |
Research & Development | 4.681 | 5.462 | 6.214 | 6.73 | 5.828 |
Operating Income | -42.211 | -38.941 | -16.768 | -22.026 | -18.92 |
Other, Net | -2.615 | -0.513 | 0.222 | 0.01 | 0.011 |
Net Income Before Taxes | -47.892 | -42.064 | -17.67 | -22.016 | -18.909 |
Net Income After Taxes | -47.892 | -42.064 | -17.67 | -22.016 | -18.909 |
Net Income Before Extra. Items | -47.892 | -42.064 | -17.67 | -22.016 | -18.909 |
Net Income | -47.892 | -42.064 | -17.67 | -22.016 | -18.909 |
Income Available to Common Excl. Extra. Items | -47.892 | -42.064 | -17.67 | -22.016 | -18.909 |
Income Available to Common Incl. Extra. Items | -47.892 | -42.064 | -17.67 | -22.016 | -18.909 |
Diluted Net Income | -47.892 | -42.064 | -17.67 | -22.016 | -18.909 |
Diluted Weighted Average Shares | 26.6316 | 26.1929 | 26.038 | 25.9899 | 25.9241 |
Diluted EPS Excluding Extraordinary Items | -1.79832 | -1.60593 | -0.67862 | -0.8471 | -0.7294 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Diluted Normalized EPS | -1.79832 | -1.60593 | -0.67862 | -0.8471 | -0.7294 |
Revenue | 2.704 | 6.596 | 17.943 | ||
Interest Income (Expense), Net Non-Operating | -3.066 | -2.61 | -1.124 | ||
Cost of Revenue, Total | 0.336 | 1.525 | |||
Gross Profit | 2.368 | 5.071 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Total Current Assets | 215.25 | 196.367 | 142.18 | 5.618 | 23.174 |
Cash and Short Term Investments | 193.372 | 192.585 | 139.147 | 5.228 | 22.311 |
Cash | 5.228 | 22.311 | |||
Prepaid Expenses | 9.075 | 3.782 | 3.033 | 0.39 | 0.863 |
Total Assets | 222.617 | 197.91 | 143.209 | 5.704 | 23.174 |
Property/Plant/Equipment, Total - Net | 5.399 | 1.482 | 0.978 | 0.066 | 0 |
Other Long Term Assets, Total | 1.082 | 0.061 | 0.051 | 0.02 | 0 |
Total Current Liabilities | 28.802 | 10.982 | 5.399 | 0.94 | 2.067 |
Accounts Payable | 6.496 | 2.279 | 0.5 | 0.462 | 0.418 |
Accrued Expenses | 22.29 | 8.685 | 4.899 | 0.478 | 1.649 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 123.08 | 11.251 | 5.911 | 0.946 | 2.067 |
Total Long Term Debt | 89.819 | 0.019 | 0 | 0 | 0 |
Other Liabilities, Total | 4.459 | 0.25 | 0.512 | 0.006 | 0 |
Total Equity | 99.537 | 186.659 | 137.298 | 4.758 | 21.107 |
Redeemable Preferred Stock | 0 | 0 | 0 | ||
Preferred Stock - Non Redeemable, Net | 0 | 43.001 | 43.001 | ||
Common Stock | 0.027 | 0.026 | 0.021 | 0.004 | 0.004 |
Additional Paid-In Capital | 354.92 | 341.384 | 221.508 | 0.273 | 0.119 |
Retained Earnings (Accumulated Deficit) | -255.41 | -154.751 | -84.231 | -38.52 | -22.017 |
Total Liabilities & Shareholders’ Equity | 222.617 | 197.91 | 143.209 | 5.704 | 23.174 |
Total Common Shares Outstanding | 26.5796 | 25.8905 | 21.3669 | 20.6123 | 20.6123 |
Cash & Equivalents | 193.372 | 192.585 | 139.147 | ||
Property/Plant/Equipment, Total - Gross | 5.636 | 1.578 | 0.997 | ||
Accumulated Depreciation, Total | -0.237 | -0.096 | -0.019 | ||
Current Port. of LT Debt/Capital Leases | 0.016 | 0.018 | |||
Capital Lease Obligations | 0.004 | 0.019 | |||
Total Receivables, Net | 6.656 | ||||
Accounts Receivable - Trade, Net | 6.656 | ||||
Total Inventory | 6.086 | ||||
Other Current Assets, Total | 0.061 | ||||
Long Term Investments | 0.886 | ||||
Long Term Debt | 89.815 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Total Current Assets | 167.354 | 215.25 | 189.686 | 158.886 | 182.648 |
Cash and Short Term Investments | 143.364 | 193.372 | 184.166 | 154.805 | 175.91 |
Cash & Equivalents | 143.364 | 193.372 | 184.166 | 154.805 | 175.91 |
Prepaid Expenses | 14.099 | 9.075 | 3.02 | 4.081 | 6.738 |
Total Assets | 176.72 | 222.617 | 195.009 | 161.503 | 184.772 |
Property/Plant/Equipment, Total - Net | 5.257 | 5.399 | 2.627 | 2.526 | 2.033 |
Other Long Term Assets, Total | 3.223 | 1.082 | 2.696 | 0.091 | 0.091 |
Total Current Liabilities | 23.026 | 28.802 | 15.161 | 9.471 | 13.736 |
Accounts Payable | 2.596 | 6.496 | 3.506 | 2.332 | 7.093 |
Accrued Expenses | 20.399 | 22.29 | 11.638 | 7.121 | 6.625 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 0.031 | 0.016 | 0.017 | 0.018 | 0.018 |
Total Liabilities | 120.727 | 123.08 | 57.497 | 9.719 | 14.124 |
Total Long Term Debt | 90.666 | 89.819 | 41.926 | 0.011 | 0.015 |
Capital Lease Obligations | 0.03 | 0.004 | 0.007 | 0.011 | 0.015 |
Other Liabilities, Total | 7.035 | 4.459 | 0.41 | 0.237 | 0.373 |
Total Equity | 55.993 | 99.537 | 137.512 | 151.784 | 170.648 |
Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.027 | 0.027 | 0.026 | 0.026 | 0.026 |
Additional Paid-In Capital | 359.268 | 354.92 | 350.832 | 347.434 | 344.282 |
Retained Earnings (Accumulated Deficit) | -303.302 | -255.41 | -213.346 | -195.676 | -173.66 |
Total Liabilities & Shareholders’ Equity | 176.72 | 222.617 | 195.009 | 161.503 | 184.772 |
Total Common Shares Outstanding | 26.6627 | 26.5796 | 26.0942 | 26.0064 | 25.9608 |
Total Receivables, Net | 5.736 | 6.656 | 2.5 | ||
Long Term Debt | 90.636 | 89.815 | 41.919 | ||
Accounts Receivable - Trade, Net | 5.736 | 6.656 | |||
Total Inventory | 4.094 | 6.086 | |||
Other Current Assets, Total | 0.061 | 0.061 | |||
Long Term Investments | 0.886 | 0.886 | |||
Property/Plant/Equipment, Total - Gross | 5.568 | ||||
Accumulated Depreciation, Total | -0.311 |
- Annual
- Quarterly
2021 | 2020 | 2019 | 2018 | 2017 | |
---|---|---|---|---|---|
Net income/Starting Line | -100.659 | -70.52 | -45.711 | -16.503 | -6.601 |
Cash From Operating Activities | -89.37 | -58.399 | -40.815 | -17.083 | -4.674 |
Non-Cash Items | 13.639 | 6.973 | 3.266 | 0.154 | 1.081 |
Changes in Working Capital | -2.491 | 5.071 | 1.611 | -0.734 | 0.846 |
Cash From Investing Activities | -1.485 | -0.7 | -0.2 | 0 | 0 |
Capital Expenditures | -1.485 | -0.7 | -0.2 | 0 | 0 |
Cash From Financing Activities | 91.642 | 112.547 | 174.985 | 0 | 26.175 |
Financing Cash Flow Items | -4.947 | -0.361 | 0 | 0 | |
Issuance (Retirement) of Stock, Net | 96.589 | 112.908 | 174.985 | 0 | 21.875 |
Issuance (Retirement) of Debt, Net | 0 | 4.3 | |||
Net Change in Cash | 0.787 | 53.448 | 133.97 | -17.083 | 21.501 |
Cash From Operating Activities | 0.141 | 0.077 | 0.019 | ||
Cash Interest Paid | 2.352 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -47.892 | -100.659 | -58.595 | -40.925 | -18.909 |
Cash From Operating Activities | -49.705 | -89.37 | -47.895 | -37.085 | -16.53 |
Cash From Operating Activities | 0.074 | 0.141 | 0.091 | 0.055 | 0.023 |
Non-Cash Items | 8.222 | 13.639 | 8.696 | 5.728 | 2.68 |
Changes in Working Capital | -10.109 | -2.491 | 1.913 | -1.943 | -0.324 |
Cash From Investing Activities | -0.085 | -1.485 | -1.25 | -0.994 | -0.34 |
Capital Expenditures | -0.085 | -1.485 | -1.25 | -0.994 | -0.34 |
Cash From Financing Activities | -0.218 | 91.642 | 40.726 | 0.299 | 0.195 |
Financing Cash Flow Items | -0.087 | -4.947 | -0.03 | -0.023 | -0.023 |
Issuance (Retirement) of Stock, Net | 0.076 | 96.589 | 0.605 | 0.322 | 0.218 |
Net Change in Cash | -50.008 | 0.787 | -8.419 | -37.78 | -16.675 |
Issuance (Retirement) of Debt, Net | -0.207 | 40.151 | |||
Cash Interest Paid | 2.067 | 2.352 |
Oyster Point Pharma, Inc. Company profile
About Oyster Point Pharma Inc
Oyster Point Pharma, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of pharmaceutical therapies to treat ophthalmic diseases. The Company's lead product candidate is TYRVAYA Nasal Spray, a nicotinic acetylcholine receptor (nAChR) agonist for the treatment of the signs and symptoms of dry eye disease. TYRVAYA Nasal Spray’s is a mechanism of action, which is designed to re-establish tear film homeostasis by stimulating the trigeminal nerve, activating the trigeminal parasympathetic pathway (TPP) and stimulating the glands and cells responsible for natural tear film production. It is sprayed into the anterior portion of the nasal cavity and stimulates nAChRs located on the chemosensory endings of the trigeminal nerve resulting in cholinergic neurotransmission.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Oyster Point Pharma Inc revenues increased from $0K to $24.5M. Net loss increased 43% to $100.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects General and administrative increase of 33% to $33.5M (expense), Stock-based Compensation in SGA increase of 22% to $7.3M (expense).
Industry: | Biotechnology & Medical Research (NEC) |
202 Carnegie Center
Suite 106
PRINCETON
NEW JERSEY 08540
US
News

EUR/USD tests key support
EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.
14:32, 21 September 2023
BoE leaves rates unchanged, GBP drops further as investors look for more clarity
The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August
11:45, 21 September 2023
GBP softer after CPI surprise, JPY focused on any further hints from Ueda
GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.
12:42, 20 September 2023
How to Trade The Break & Retest
In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.
11:59, 20 September 2023
Cable coils near lows ahead of Fed and BoE rate decisions
It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.
14:16, 19 September 2023
FTSE 100 Technical Outlook - 18 September 2023
In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.
06:55, 19 September 2023
Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally
The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.
13:46, 15 September 2023People also watch
Still looking for a broker you can trust?
Join the 555.000+ traders worldwide that chose to trade with Capital.com